Tony Fiorino, M.D., Ph.D.
CHIEF MEDICAL ADVISOR
Dr. Fiorino became Chief Medical Advisor to BrainStorm since September 2015, filling the role left vacant by the demise of Professor Eldal Melamed. He previously served as BrainStorm’s Chief Executive Officer, from June 2014 through September 2015, during which he made substantial contributions to the NurOwn® clinical development program. Dr. Fiorino is an experienced biotechnology executive, entrepreneur and investor with expertise in clinical drug development, biotechnology finance and portfolio management.
He is currently President and CEO of Triumvira Immunologics, a private biotechnology company developing an engineered T cell platform for various oncology indications. Before his tenure at BrainStorm, he was the founding President and CEO of EnzymeRx, where he successfully developed pegylated uricase through phase 2 studies and led its sale to 3SBio. Dr. Fiorino also brings a wealth of broader experience in his prior role as a biotechnology analyst and investor, having been a portfolio manager at several healthcare hedge funds and long-only institutional equity funds.
Professor Daniel Offen, Ph.D.
CHIEF SCIENTIFIC ADVISOR
Professor Offen, who enjoys an internationally recognized reputation in neuroscience research, is a scientific founder of BrainStorm Cell Therapeutics together with Professor Eldad Melamed.
Prof. Offen continues to be a key academic collaborator with BrainStorm on multiple preclinical projects. Since 1993 he has been head of the Neuroscience Laboratory at Tel Aviv University School of Medicine. He has lectured extensively, both at Tel Aviv University and international scientific conferences, and has supervised many PhD students. Dr. Offen has published over 100 original scientific papers and several patents. Dr. Offen is a member of the Scientific Committee of the Israel Society for Neuroscience.